Gulati S, Atzpodien J, Lemoli R M, Shimazaki C, Clarkson B
Laboratory of Hematopoietic Cell Kinetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Prog Clin Biol Res. 1990;333:87-102.
The potential of various photoradiation therapy for the in vitro purging of residual tumor cells from autologous bone marrow (BM) transplants is discussed in this paper. The results with fluorescent dyes, Dihematoporphyrin Ether (DHE) and Merocyanine-540 (MC-540) are detailed. Following photoradiation of cells with white light, both DHE and MC-540 showed high cytocidal activity towards lymphoid and myeloid neoplastic cells, but had significantly less effect on normal granulocyte-macrophage (CFU-GM), erythroid (BFU-E) and mixed colony-forming (CFU-GEMM) progenitor cells. Acute promyelocytic leukemia (HL-60), non-B, non-T, cALLa positive acute lymphoblastic leukemia (Reh), and diffuse histiocytic B-cell lymphoma (SK-DHL-2) cell lines were exposed to different drug concentrations in combination with white light at a constant illumination rate of 50,000 lux. With DHE doses varying from 2.0 to 2.5 ug/ml and MC-540 concentrations of 15 to 20 ug/ml, clonogenic tumor cells could be reduced by more than 4 logs, when treated alone or in mixtures with normal irradiated human marrow cells. However, preferential cytotoxicity towards neoplastic cells was highly dependent on the mode of light activation. MC-540 had no substantial effect on malignant lymphoid (SK-DHL-2) and myeloid (HL-60) cells, and on normal marrow myeloid (CFU-GM) precursors, when the drug incubation was performed in the dark and followed by light exposure of washed cells. Equal doses of MC-540 (15-20 ug/ml) could preferentially eliminate tumor cells under conditions of simultaneous light and drug treatment (30 minutes at 37 degrees C). Using DHE (2.5 ug/ml), 29.3%, 46.8%, and 27.5% of normal marrow CFU-GM, BFU-E, and CFU-GEMM, respectively, were spared, following sequential drug and light exposure of cells, while simultaneous treatment reduced both normal (CFU-GM) and neoplastic cells below the limits of detection. The data from various centers is briefly discussed with special emphasis on clinical trials. Our results provide a useful model for leukemia and lymphoma cells and suggest that these phototherapy experiments can be implemented into clinical trials.
本文讨论了各种光辐射疗法用于体外清除自体骨髓移植中残留肿瘤细胞的潜力。详细介绍了使用荧光染料二血卟啉醚(DHE)和部花青-540(MC-540)的结果。在用白光对细胞进行光辐射后,DHE和MC-540对淋巴样和髓样肿瘤细胞均显示出高杀细胞活性,但对正常粒细胞-巨噬细胞(CFU-GM)、红系(BFU-E)和混合集落形成(CFU-GEMM)祖细胞的影响明显较小。将急性早幼粒细胞白血病(HL-60)、非B非T、cALLa阳性急性淋巴细胞白血病(Reh)和弥漫性组织细胞性B细胞淋巴瘤(SK-DHL-2)细胞系暴露于不同药物浓度,并以50,000勒克斯的恒定光照速率与白光联合处理。当单独使用或与正常照射的人骨髓细胞混合使用时,DHE剂量为2.0至2.5微克/毫升,MC-540浓度为15至20微克/毫升,可使克隆形成肿瘤细胞减少超过4个对数级。然而,对肿瘤细胞的优先细胞毒性高度依赖于光激活模式。当在黑暗中进行药物孵育,然后对洗涤后的细胞进行光照时,MC-540对恶性淋巴样(SK-DHL-2)和髓样(HL-60)细胞以及正常骨髓髓样(CFU-GM)前体细胞没有实质性影响。在同时进行光照和药物处理的条件下(37℃下30分钟),等量的MC-540(15 - 20微克/毫升)可优先清除肿瘤细胞。使用DHE(2.5微克/毫升)时,在细胞先进行药物处理然后光照的情况下,分别有29.3%、46.8%和27.5%的正常骨髓CFU-GM、BFU-E和CFU-GEMM得以保留,而同时处理则使正常(CFU-GM)和肿瘤细胞均降至检测限以下。简要讨论了来自各个中心的数据,特别强调了临床试验。我们的结果为白血病和淋巴瘤细胞提供了一个有用的模型,并表明这些光疗实验可应用于临床试验。